Showing results (11-20 of 76) with videos related to
Sort By:
Pageof 8
Archives of Pathology & Laboratory Medicine|November 18, 2017
Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical ImplicationsEsmeralda Celia Marginean, Barbara MeloskyClinical Lung Cancer|July 3, 2017
An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic ApproachBarbara Melosky, Sanjay Popat, David R GandaraClinical Lung Cancer|June 11, 2019
Outcome Differences Between First- and Second-generation EGFR Inhibitors in Advanced EGFR Mutated NSCLC in a Large Population-based CohortSally C Lau, Negar Chooback, Cheryl Ho, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 5, 2011
Erlotinib or docetaxel for second-line treatment of non-small cell lung cancer: a real-world cost-effectiveness analysisIan Cromwell, Kimberly van der Hoek, Barbara Melosky, et al.Current Oncology (Toronto, Ont.)|December 23, 2021
Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) PatientsYuti P Patel, Donald Husereau, Natasha B Leighl, et al.Lung Cancer (Amsterdam, Netherlands)|June 1, 2005
Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North AmericaCheryl Ho, Nevin Murray, Janessa Laskin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint InhibitionBarbara Melosky, Quincy Chu, Rosalyn Juergens, et al.Current Oncology (Toronto, Ont.)|February 24, 2022
A Case of ALK-Rearranged Combined Lung Adenocarcinoma and Neuroendocrine Carcinoma with Diffuse Bone Metastasis and Partial Response to AlectinibChloe A Lim, Norbert Banyi, Tracy Tucker, et al.Future Oncology (London, England)|April 15, 2021
EGFR tyrosine kinase inhibitors for <i>EGFR</i> mutation-positive non-small-cell lung cancer: outcomes in Asian populationsEdward S Kim, Barbara Melosky, Keunchil Park, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 27, 2014
Less toxic chemotherapy improves uptake of all lines of chemotherapy in advanced non-small-cell lung cancer: a 10-year retrospective population-based reviewCheryl Ho, Katherine Ramsden, Yongliang Zhai, et al.Pageof 8